In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633.
Average rating
Cast your vote
You can rate an item by clicking the amount of stars they wish to award to this item.
When enough users have cast their vote on this item, the average rating will also be shown.
Star rating
Your vote was cast
Thank you for your feedback
Thank you for your feedback
Issue Date
2017-02
Metadata
Show full item recordAbstract
CHF5633 is a new generation synthetic surfactant containing both SP-B and SP-C analogues developed for the treatment of respiratory distress syndrome. Here, the optimal dose and its performance in comparison to the animal-derived surfactant poractant alfa were investigated.Citation
In vitro and in vivo comparison between poractant alfa and the new generation synthetic surfactant CHF5633. 2017, 81 (2):369-375 Pediatr. Res.Affiliation
Helmholtz Institut für pharmazeutische Forschung Saarland, Universitätscampus E8.1, 66123 Saarbrücken, Germany.Journal
Pediatric researchPubMed ID
27973472Type
ArticleLanguage
enISSN
1530-0447ae974a485f413a2113503eed53cd6c53
10.1038/pr.2016.231
Scopus Count
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as http://creativecommons.org/licenses/by-nc-sa/4.0/